JPH10508756A - 造血タンパク質を用いて赤血球形成を刺激する方法 - Google Patents
造血タンパク質を用いて赤血球形成を刺激する方法Info
- Publication number
- JPH10508756A JPH10508756A JP8516916A JP51691696A JPH10508756A JP H10508756 A JPH10508756 A JP H10508756A JP 8516916 A JP8516916 A JP 8516916A JP 51691696 A JP51691696 A JP 51691696A JP H10508756 A JPH10508756 A JP H10508756A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- acid residues
- tpo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.TPO なしで培養する場合に比べて赤血球または赤血球前駆体の生成数を増 大させるのに十分な量のトロンボポイエチン(TPO)およびエリトロポイエチン(EP O)を含んでなる組成物とともに骨髄細胞または末梢血細胞を培養することからな る、赤血球形成を生体外で刺激する方法であって;TPO が、 配列番号:2に示す28位〜172位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜207位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜235位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜266位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜207位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜235位のアミノ酸残基のアミノ酸配列;および 配列番号:2に示す22位〜266位のアミノ酸残基のアミノ酸配列; からなる群から選択されるアミノ酸配列を含んでなる方法。 2.TPO なしで培養する場合に比べて赤血球または赤血球前駆体の生成数を増 大させるのに十分な量のTPO とともに骨髄細胞または末梢血細胞を培養すること からなる、赤血球形成を生体外で刺激する方法であって;TPO が、 配列番号:2に示す28位〜172位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜207位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜235位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜266位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜207位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜235位のアミノ酸残基のアミノ酸配列;および 配列番号:2に示す22位〜266位のアミノ酸残基のアミノ酸配列; からなる群から選択されるアミノ酸配列を含んでなる方法。 3.赤血球細胞の増殖または分化を高めるのに十分な量で、医薬として許容さ れる賦形剤と組み合わせて、TPO を含んでなる組成物を、赤血球形成の刺激を必 要とする哺乳類に投与することからなる赤血球形成を刺激する方法であって;TP O が 配列番号:2に示す28位〜172位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜207位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜235位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜266位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜207位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜235位のアミノ酸残基のアミノ酸配列;および 配列番号:2に示す22位〜266位のアミノ酸残基のアミノ酸配列; からなる群から選択されるアミノ酸配列を含んでなる方法。 4.赤血球細胞の増殖または分化を高めるのに十分な量で、医薬として許容さ れる賦形剤と組み合わせて、TPO およびEPO を含んでなる組成物を、赤血球形成 の刺激を必要とする哺乳類に投与することからなる赤血球形成を刺激する方法で あって;TPO が、 配列番号:2に示す28位〜172位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜207位のアミノ酸残基のアミノ酸配列; 配列番号;2に示す28位〜235位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す28位〜266位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜185位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜193位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜198位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜207位のアミノ酸残基のアミノ酸配列; 配列番号:2に示す22位〜235位のアミノ酸残基のアミノ酸配列;および 配列番号:2に示す22位〜266位のアミノ酸残基のアミノ酸配列; からなる群から選択されるアミノ酸配列を含んでなる方法。 5.TPO なしで培養する場合に比べて赤血球または赤血球前駆体の生成数を増 大させるのに十分な量のトロンボポイエチン(TPO)およびエリトロポイエチン(EP O)を含んでなる組成物とともに骨髄細胞または末梢血細胞を培養することからな る、赤血球形成を生体外で刺激する方法であって;TPO の量が100pg/ml〜10ng /mlでありかつEPO の量が0.5単位/ml〜5単位/mlである方法。 6.TPO なしで培養する場合に比べて赤血球または赤血球前駆体の生成数を増 大させるのに十分な量のトロンボポイエチン(TPO)を 含んでなる組成物とともに骨髄細胞または末梢血細胞を培養することからなる、 赤血球形成を生体外で刺激する方法であって;TPO の量が100pg/ml〜10ng/ml である方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33556694A | 1994-11-07 | 1994-11-07 | |
US08/335,566 | 1994-11-07 | ||
US34774894A | 1994-12-01 | 1994-12-01 | |
US08/347,748 | 1994-12-01 | ||
US08/461,819 | 1995-06-05 | ||
US08/461,819 US6316254B1 (en) | 1994-02-14 | 1995-06-05 | Methods for stimulating erythropoiesis using hematopoietic proteins |
PCT/US1995/014425 WO1996015758A2 (en) | 1994-11-07 | 1995-11-07 | Methods for stimulating erythropoiesis using thrombopoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10508756A true JPH10508756A (ja) | 1998-09-02 |
Family
ID=27407066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8516916A Ceased JPH10508756A (ja) | 1994-11-07 | 1995-11-07 | 造血タンパク質を用いて赤血球形成を刺激する方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US6316254B1 (ja) |
JP (1) | JPH10508756A (ja) |
KR (1) | KR970706838A (ja) |
CN (1) | CN1173136A (ja) |
AU (1) | AU4462296A (ja) |
WO (1) | WO1996015758A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361330B2 (en) * | 1995-10-04 | 2008-04-22 | Immunex Corporation | Methods of using flt3-ligand in the treatment of fibrosarcoma |
US20020034517A1 (en) * | 1995-10-04 | 2002-03-21 | Kenneth Brasel | Dendritic cell stimulatory factor |
WO2002015926A1 (fr) * | 2000-08-24 | 2002-02-28 | Kirin Beer Kabushiki Kaisha | Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes |
US8168589B2 (en) * | 2000-09-04 | 2012-05-01 | Hannelore Ehrenreich | Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
US7588745B2 (en) * | 2004-04-13 | 2009-09-15 | Si Options, Llc | Silicon-containing products |
SG188143A1 (en) | 2008-02-08 | 2013-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
NZ591235A (en) | 2008-07-23 | 2012-07-27 | Ambrx Inc | Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis |
PL2342223T3 (pl) | 2008-09-26 | 2017-09-29 | Ambrx, Inc. | Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania |
EP2446034A4 (en) * | 2009-06-22 | 2013-11-27 | Ipca Lab Ltd | NOVEL POLYNUCLEOTIDE MOLECULES FOR IMPROVED GENE EXPRESSION |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
MX2019000205A (es) * | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920703641A (ko) | 1990-12-28 | 1992-12-18 | 유미꾸라 레이이찌 | 신규한 거핵구 증폭인자 및 그의 제조방법 |
CA2169173C (en) * | 1994-02-14 | 2002-10-15 | Kenneth Kaushansky | Methods for stimulating erythropoiesis using thrombopoietin |
US5571686A (en) | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
-
1995
- 1995-06-05 US US08/461,819 patent/US6316254B1/en not_active Expired - Fee Related
- 1995-11-07 CN CN95196702A patent/CN1173136A/zh active Pending
- 1995-11-07 KR KR1019970703034A patent/KR970706838A/ko active IP Right Grant
- 1995-11-07 JP JP8516916A patent/JPH10508756A/ja not_active Ceased
- 1995-11-07 AU AU44622/96A patent/AU4462296A/en not_active Abandoned
- 1995-11-07 WO PCT/US1995/014425 patent/WO1996015758A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO1996015758A3 (en) | 1996-07-11 |
WO1996015758A2 (en) | 1996-05-30 |
AU4462296A (en) | 1996-06-17 |
CN1173136A (zh) | 1998-02-11 |
US6316254B1 (en) | 2001-11-13 |
KR970706838A (ko) | 1997-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100319359B1 (ko) | flt3수용체에대한리간드 | |
JP5558213B2 (ja) | 貧血の予防および治療用の方法および組成物 | |
CA2169173C (en) | Methods for stimulating erythropoiesis using thrombopoietin | |
KR100320106B1 (ko) | 트롬보포이에틴폴리펩티드분비방법 | |
JP2688539B2 (ja) | ほ乳類サイトカイン、il―11 | |
JP2657113B2 (ja) | 幹細胞因子 | |
DE60103052T2 (de) | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten | |
JP5231214B2 (ja) | エリスロポエチン変異体 | |
CZ49097A3 (cs) | Čištěný a izolovaný polypeptid, jeho použití, DNA sekvence pro jeho expresi a farmaceutická kompozice | |
JP2003530874A (ja) | 貧血の予防及び治療用の方法及び組成物 | |
JPH05503003A (ja) | 潜在性関与ペプチドおよびその使用 | |
JP2002512006A (ja) | TNF受容体スーパーファミリーの一員である成熟FLINT(mFLINT)ポリペプチド、または、OPG3の治療上の適用 | |
JPH11512709A (ja) | 截形グリア細胞系由来神経栄養因子 | |
US5188828A (en) | Interleukin-6 to stimulate erythropoietin production | |
JPH10508756A (ja) | 造血タンパク質を用いて赤血球形成を刺激する方法 | |
JP2001511010A (ja) | ヒトsdf−5蛋白および組成物 | |
US6475781B1 (en) | Trans-dominant suppressor genes for oligomeric proteins | |
US6258352B1 (en) | Compositions and methods of treating thrombocytopenia with IL-15 | |
US6207454B1 (en) | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide | |
US6099830A (en) | Methods for stimulating erythropoiesis using hematopoietic proteins | |
JPH10511681A (ja) | 精製されたトロンボポエチン及びその製造方法 | |
EP0506716B1 (en) | Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor | |
Cowling et al. | Erythropoietin and myeloid colony stimulating factors | |
AU725159B2 (en) | Methods for stimulating erythropoiesis using thrombopoietin | |
JP2003520761A (ja) | Flintポリペプチドの治療用への適用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050920 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051031 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060206 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060314 |